NEW YORK (GenomeWeb News) - Abbott and Epigenomics have penned a non-exclusive license and collaboration agreement to develop a colorectal cancer diagnostic based on Epigenomics' intellectual property, Epigenomics said today.
Under the terms of the agreement, Abbott has licensed worldwide rights to Epigenomics’ DNA methylation biomarker Septin 9, which the companies plan to develop into an in vitro diagnostic blood test for early detection of colorectal cancer.
The companies plan to launch a CE-marked test in Europe in 2009, and plan to file for approval with the US Food and Drug Administration in 2010.
Under the deal, Abbott will give Epigenomics and up-front fee, milestone payments, and royalties from sales of the test. A side provision in the agreement allows Abbott to evaluate Epigenomics' "other proprietary biomarkers for additional cancer indications."
Epigenomics said this test will be the first cancer diagnostic to run on Abbott's m2000 platform.